{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:54Z","timestamp":1784808114111,"version":"3.55.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.2217\/ijh-2021-0010","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:31:08Z","timestamp":1715949068000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia"],"prefix":"10.2217","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1673","authenticated-orcid":false,"given":"Guray","family":"Saydam","sequence":"first","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-3399","authenticated-orcid":false,"given":"Ridvan","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Uludag University Medical Faculty Hospital, Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-5405","authenticated-orcid":false,"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Trakya University Medical Faculty Hospital, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Istanbul University Cerrahpa\u015fa Faculty Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-5673","authenticated-orcid":false,"given":"Birol","family":"Guvenc","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Cukurova University Medical Faculty Hospital, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-9462","authenticated-orcid":false,"given":"Ibrahim Celalettin","family":"Haznedaroglu","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Hacettepe University Medical Faculty Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-5908","authenticated-orcid":false,"given":"Mehmet Ali","family":"Ozcan","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Dokuz Eylul University Medical Faculty Hospital, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-0189","authenticated-orcid":false,"given":"Ozan","family":"Salim","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Akdeniz University Medical Faculty Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-4371","authenticated-orcid":false,"given":"Mehmet","family":"Sonmez","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Karadeniz Technical University Medical Faculty Hospital, Trabzon, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-7545","authenticated-orcid":false,"given":"Ayse Tulin","family":"Tuglular","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Marmara University Medical Faculty Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-0232","authenticated-orcid":false,"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Ondokuz May\u0131s University Medical Faculty Hospital, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7011-3412","authenticated-orcid":false,"given":"Ali","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Erciyes University Medical Faculty Hospital, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-6883","authenticated-orcid":false,"given":"Birkan","family":"Aver","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pfizer Pharmaceuticals, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-8174","authenticated-orcid":false,"given":"Sirac","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pfizer Pharmaceuticals, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-6664","authenticated-orcid":false,"given":"Begum","family":"Ozdengulsun","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pfizer Pharmaceuticals, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1665-372X","authenticated-orcid":false,"given":"Osman","family":"Ilhan","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Division of Hematology, Ankara University Medical Faculty Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24249"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3095.3095"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"issue":"10","key":"e_1_3_3_8_1","first-page":"1395","article-title":"Severe adverse events associated with the use of second line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent P","year":"2011","unstructured":"ValentP. Severe adverse events associated with the use of second line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 96(10), 1395\u20131397 (2011).","journal-title":"Haematologica"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14580"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70040-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02513.x"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16971"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2541-6"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.008"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.011"},{"key":"e_1_3_3_18_1","volume-title":"24th Congress of the European Hematology Association (EHA).","author":"Saydam G","year":"2019","unstructured":"SaydamG, UnalA, KurtogluEet al. Demographic\/clinical features and treatment outcomes of chronic phase chronic myeloid leukemia patients in Turkey: real-world data. Presented at: 24th Congress of the European Hematology Association (EHA). Amsterdam, The Netherlands (13\u201316 June 2019)."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.837279"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2074-3"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.993391"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.11.002"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.04.005"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000165"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-019-00321-z"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.313353"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0309-2"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2820-x"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.07.007"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.07.019"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.245"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5932"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.007"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.09.012"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188987"},{"key":"e_1_3_3_45_1","first-page":"237","article-title":"Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial","volume":"99","author":"Rousselot P","year":"2014","unstructured":"RousselotP, MollicaL, Guerci-BreslerAet al. Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial. Haematologica 99, 237\u2013238 (2014).","journal-title":"Haematologica"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247767"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211665"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv172"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1347929"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966120"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.020"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216682311"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2335"},{"issue":"4","key":"e_1_3_3_56_1","first-page":"1719","article-title":"Drug-drug interactions in patient using tyrosine kinase inhibitors: a multicenter retrospective study","volume":"24","author":"Ergun Y","year":"2019","unstructured":"ErgunY, OzdemirNY, ToptasSet al. Drug-drug interactions in patient using tyrosine kinase inhibitors: a multicenter retrospective study. JBUON 24(4), 1719\u20131726 (2019).","journal-title":"JBUON"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3413-7"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S129821"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13716"}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh-2021-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:31:12Z","timestamp":1715949072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh-2021-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.2217\/ijh-2021-0010"],"URL":"https:\/\/doi.org\/10.2217\/ijh-2021-0010","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"IJH38"}}